The next iteration of Ancestry's Health experience seeks to provide customers with actionable information about certain commonly inherited health conditions.
According to the company, the test has shown to be more sensitive and accurate than a COVID-19 anterior nasal swab test in the firm's EUA validation study.
The company has developed a microscopy system that allows imaging of a full pathology slide in 21 channels with a single staining process and a rapid turnaround time.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
The Bay Area startup is offering a no-touch method to separate cell populations for downstream analysis in genomics and synthetic biology applications.